GSK plc (NYSE: GSK) Stock Competitors & Peer Comparison
See GSK's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GSK and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK | $50.22 | -1.65% | 100.6B | 10.85 | $4.63 | +3.62% |
| LLY | $1,152.22 | -0.02% | 1.1T | 36.61 | $31.49 | +0.58% |
| JNJ | $269.99 | -0.09% | 650.6B | 25.16 | $10.73 | +1.94% |
| ABBV | $263.78 | -0.09% | 466.1B | 25.89 | $10.19 | +2.58% |
| MRK | $146.76 | -0.27% | 362.5B | 45.72 | $3.21 | +2.32% |
| NVS | $140.37 | -0.39% | 266.8B | 16.15 | $8.69 | +3.38% |
| AZN | $166.08 | -0.04% | 257.5B | 17.93 | $9.26 | +1.94% |
| AMGN | $385.65 | +2.47% | 205B | 16.98 | $22.37 | +2.58% |
| NVO | $43.24 | +0.12% | 192B | 10.76 | $4.02 | +4.13% |
| GILD | $150.11 | -0.52% | 186.4B | -384.90 | -$0.39 | +2.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
GSK vs LLY Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while LLY trades at $1,152.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas LLY's P/E ratio is 36.61. In terms of profitability, GSK's ROE is +0.24%, compared to LLY's ROE of +0.93%. Regarding short-term risk, GSK is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for GSK.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
GSK vs JNJ Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, JNJ has a market cap of 650.6B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while JNJ trades at $269.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas JNJ's P/E ratio is 25.16. In terms of profitability, GSK's ROE is +0.24%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, GSK is less volatile compared to JNJ. This indicates lower risk in terms of short-term price fluctuations for GSK.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
GSK vs ABBV Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, ABBV has a market cap of 466.1B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while ABBV trades at $263.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas ABBV's P/E ratio is 25.89. In terms of profitability, GSK's ROE is +0.24%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, GSK is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for GSK.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
GSK vs MRK Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, MRK has a market cap of 362.5B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while MRK trades at $146.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas MRK's P/E ratio is 45.72. In terms of profitability, GSK's ROE is +0.24%, compared to MRK's ROE of +0.07%. Regarding short-term risk, GSK is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for GSK.Check MRK's competition here
Novartis AG (NYSE: NVS)
GSK vs NVS Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, NVS has a market cap of 266.8B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while NVS trades at $140.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas NVS's P/E ratio is 16.15. In terms of profitability, GSK's ROE is +0.24%, compared to NVS's ROE of +0.30%. Regarding short-term risk, GSK is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for GSK.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
GSK vs AZN Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, AZN has a market cap of 257.5B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while AZN trades at $166.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas AZN's P/E ratio is 17.93. In terms of profitability, GSK's ROE is +0.24%, compared to AZN's ROE of +0.22%. Regarding short-term risk, GSK is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for GSK.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
GSK vs AMGN Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, AMGN has a market cap of 205B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while AMGN trades at $385.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas AMGN's P/E ratio is 16.98. In terms of profitability, GSK's ROE is +0.24%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, GSK is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
GSK vs NVO Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, NVO has a market cap of 192B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while NVO trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas NVO's P/E ratio is 10.76. In terms of profitability, GSK's ROE is +0.24%, compared to NVO's ROE of +0.59%. Regarding short-term risk, GSK is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for GSK.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
GSK vs GILD Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, GILD has a market cap of 186.4B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while GILD trades at $150.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas GILD's P/E ratio is -384.90. In terms of profitability, GSK's ROE is +0.24%, compared to GILD's ROE of -0.16%. Regarding short-term risk, GSK is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for GSK.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
GSK vs PFE Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, PFE has a market cap of 157.3B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while PFE trades at $27.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas PFE's P/E ratio is 9.05. In terms of profitability, GSK's ROE is +0.24%, compared to PFE's ROE of +0.05%. Regarding short-term risk, GSK is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for GSK.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
GSK vs BMY Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, BMY has a market cap of 128.8B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while BMY trades at $63.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas BMY's P/E ratio is 10.63. In terms of profitability, GSK's ROE is +0.24%, compared to BMY's ROE of +0.47%. Regarding short-term risk, GSK is more volatile compared to BMY. This indicates higher risk in terms of short-term price fluctuations for GSK.Check BMY's competition here
Sanofi (NASDAQ: SNY)
GSK vs SNY Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, SNY has a market cap of 102B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while SNY trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas SNY's P/E ratio is 9.25. In terms of profitability, GSK's ROE is +0.24%, compared to SNY's ROE of +0.06%. Regarding short-term risk, GSK is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for GSK.Check SNY's competition here
Biogen Inc. (NASDAQ: BIIB)
GSK vs BIIB Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, BIIB has a market cap of 31.8B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while BIIB trades at $215.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas BIIB's P/E ratio is 13.60. In terms of profitability, GSK's ROE is +0.24%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, GSK is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
GSK vs HZNP Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GSK's ROE is +0.24%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GSK is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for GSK.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
GSK vs GRFS Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while GRFS trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas GRFS's P/E ratio is 8.40. In terms of profitability, GSK's ROE is +0.24%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, GSK is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for GSK.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
GSK vs OGN Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while OGN trades at $13.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas OGN's P/E ratio is 4.09. In terms of profitability, GSK's ROE is +0.24%, compared to OGN's ROE of +0.23%. Regarding short-term risk, GSK is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for GSK.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
GSK vs AMRN Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, AMRN has a market cap of 286.9M. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while AMRN trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas AMRN's P/E ratio is -138.70. In terms of profitability, GSK's ROE is +0.24%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, GSK is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for GSK.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
GSK vs SCLX Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, SCLX has a market cap of 42.8M. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while SCLX trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas SCLX's P/E ratio is -0.13. In terms of profitability, GSK's ROE is +0.24%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for GSK.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
GSK vs MIRA Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, MIRA has a market cap of 34.2M. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while MIRA trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas MIRA's P/E ratio is -0.56. In terms of profitability, GSK's ROE is +0.24%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, GSK is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for GSK.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
GSK vs SCLXW Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, SCLXW has a market cap of 33.6M. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while SCLXW trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GSK's ROE is +0.24%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, GSK is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for GSK.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
GSK vs BDSIW Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, GSK's ROE is +0.24%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, GSK is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for GSK.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
GSK vs CRXT Comparison September 2026
GSK plc (NYSE: GSK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK stands at 100.6B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, GSK is priced at $50.22 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK currently has a P/E ratio of 10.85, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GSK's ROE is +0.24%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GSK is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for GSK.Check CRXT's competition here